BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T, Dinesh T, Duncan CJA, England A, Faust SN, Ferreira DM, Finn A, Goodman AL, Green CA, Hallis B, Heath PT, Hill H, Horsington BM, Lambe T, Lazarus R, Libri V, Lillie PJ, Mujadidi YF, Payne R, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screaton GR, Singh N, Turner DPJ, Turner PJ, Vichos I, White R, Nguyen-Van-Tam JS, Snape MD; Com-COV2 Study Group. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2022;399:36-49. [PMID: 34883053 DOI: 10.1016/S0140-6736(21)02718-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 83.0] [Reference Citation Analysis]
Number Citing Articles
1 He Q, Liu S, Liang Z, Lu S, Cun W, Mao Q. Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses. Emerg Microbes Infect 2023;12:2152388. [PMID: 36426608 DOI: 10.1080/22221751.2022.2152388] [Reference Citation Analysis]
2 Toledo-Romaní ME, García-Carmenate M, Valenzuela-Silva C, Baldoquín-Rodríguez W, Martínez-Pérez M, Rodríguez-González M, Paredes-Moreno B, Mendoza-Hernández I, González-Mujica Romero R, Samón-Tabio O, Velazco-Villares P, Bacallao-Castillo JP, Licea-Martín E, Rodríguez-Ortega M, Herrera-Marrero N, Caballero-González E, Egües-Torres L, Duartes-González R, García-Blanco S, Pérez-Cabrera S, Huete-Ferreira S, Idalmis-Cisnero K, Fonte-Galindo O, Meliá-Pérez D, Rojas-Remedios I, Doroud D, Gouya MM, Biglari A, Fernández-Castillo S, Climent-Ruiz Y, Valdes-Balbín Y, García-Rivera D, Van der Stuyft P, Verez-Bencomo V; SOBERANA Phase 3 team. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. Lancet Reg Health Am 2023;18:100423. [PMID: 36618081 DOI: 10.1016/j.lana.2022.100423] [Reference Citation Analysis]
3 Chevaisrakul P, Lumjiaktase P, Kietdumrongwong P, Chuatrisorn I, Chatsangjaroen P, Phanuphak N. Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program. Sci Rep 2023;13:763. [PMID: 36641523 DOI: 10.1038/s41598-023-28101-5] [Reference Citation Analysis]
4 Liu M, Sun J, Li Y, Shao N. Is it possible to flatten-the-curve after the initial outbreak of Covid-19? A data-driven modeling analysis for Omicron pandemic in China.. [DOI: 10.21203/rs.3.rs-2404162/v1] [Reference Citation Analysis]
5 Sousa JP, Roque D, Guerreiro C, Teixeira R; Studies Committee of the Portuguese Society of Cardiology. Anti-SARS-CoV-2 vaccine-induced myocarditis - Real but, in general, rare and mild: A consensus statement from the Studies Committee of the Portuguese Society of Cardiology. Rev Port Cardiol 2023:S0870-2551(23)00017-3. [PMID: 36621565 DOI: 10.1016/j.repc.2023.01.003] [Reference Citation Analysis]
6 Mentzer AJ, O'Connor D, Bibi S, Chelysheva I, Clutterbuck EA, Demissie T, Dinesh T, Edwards NJ, Felle S, Feng S, Flaxman AL, Karp-Tatham E, Li G, Liu X, Marchevsky N, Godfrey L, Makinson R, Bull MB, Fowler J, Alamad B, Malinauskas T, Chong AY, Sanders K, Shaw RH, Voysey M, Snape MD, Pollard AJ, Lambe T, Knight JC; Oxford COVID Vaccine Trial Genetics Study Team Group. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nat Med 2023;29:147-57. [PMID: 36228659 DOI: 10.1038/s41591-022-02078-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Chen P, Shi X, He W, Zhong G, Tang Y, Wang H, Zhang P. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. Hum Vaccin Immunother 2022;18:2040330. [PMID: 35321627 DOI: 10.1080/21645515.2022.2040330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Shahjin F, Patel M, Machhi J, Cohen JD, Nayan MU, Yeapuri P, Zhang C, Waight E, Hasan M, Abdelmoaty MM, Dash PK, Zhou Y, Andreu I, Gendelman HE, Kevadiya BD. Multipolymer microsphere delivery of SARS-CoV-2 antigens. Acta Biomater 2022:S1742-7061(22)00853-4. [PMID: 36581007 DOI: 10.1016/j.actbio.2022.12.043] [Reference Citation Analysis]
9 Mudenda M, Kimani J, Kinyua J, Kimotho J. Preliminary In Vivo Evidence of Oral Selenium Supplementation as a Potentiating Agent on a Vector-Based COVID-19 Vaccine in BALB/c Mice. Vaccines (Basel) 2022;11. [PMID: 36679902 DOI: 10.3390/vaccines11010057] [Reference Citation Analysis]
10 Touizer E, Alrubayyi A, Ford R, Hussain N, Gerber PP, Shum HL, Rees-Spear C, Muir L, Gea-Mallorquí E, Kopycinski J, Jankovic D, Jeffery-Smith A, Pinder CL, Fox TA, Williams I, Mullender C, Maan I, Waters L, Johnson M, Madge S, Youle M, Barber TJ, Burns F, Kinloch S, Rowland-Jones S, Gilson R, Matheson NJ, Morris E, Peppa D, McCoy LE. Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. iScience 2023;26:105862. [PMID: 36590902 DOI: 10.1016/j.isci.2022.105862] [Reference Citation Analysis]
11 Sun J, Li Y, Shao N, Liu M. Is it possible to flatten-the-curve after the initial outbreak of Covid-19? A data-driven modeling analysis for Omicron pandemic in China.. [DOI: 10.1101/2022.12.21.22283786] [Reference Citation Analysis]
12 Mazyar Shadman, Catherine Liu, Katherine Eakle, Hwai J. Hiew, Juliana M.L. Biondo, Paolo Ghia, Anthony R. Mato. COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia. Hemasphere 2022;7:e811. [ DOI: 10.1097/HS9.0000000000000811] [Reference Citation Analysis]
13 Kodali L, Budhiraja P, Gea-Banacloche J. COVID-19 in kidney transplantation-implications for immunosuppression and vaccination. Front Med (Lausanne) 2022;9:1060265. [PMID: 36507509 DOI: 10.3389/fmed.2022.1060265] [Reference Citation Analysis]
14 Bracke C, Miranda C, González S, Casas I, Cardona PJ, Benitez RM, Sopena N, Reynaga EA, Massanella M, Clotet B, Carrillo J, Mateu L, Pedro-botet ML. Correlation between Clinical and Immunological Variables and Humoral Response to SARS-CoV-2 Vaccination in Adult Patients with Antibody Deficiency Disorders. Pathogens 2022;11:1364. [DOI: 10.3390/pathogens11111364] [Reference Citation Analysis]
15 Khong K, Zhang R, Hung IF. The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. Vaccines 2022;10:1924. [DOI: 10.3390/vaccines10111924] [Reference Citation Analysis]
16 Liao SH, Chang WJ, Hsu CY, Ming-Fang Yen A, Lin TY, Li-Sheng Chen S, Hsiu-Hsi Chen T. Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity. Vaccine 2022;40:6864-72. [PMID: 36270891 DOI: 10.1016/j.vaccine.2022.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hackstein CP, Klenerman P. Emerging features of MAIT cells and other unconventional T cell populations in human viral disease and vaccination. Semin Immunol 2022;61-64:101661. [PMID: 36374780 DOI: 10.1016/j.smim.2022.101661] [Reference Citation Analysis]
18 Pfrommer LR, Schoeps M, Blettner M, Wollschläger D, Herm-Stapelberg N, Mittnacht L, Kachel P, Jahn K, Loewenich FDV, Gianicolo EAL. Self-Reported Reactogenicity After Different COVID-19 Vaccination Regimens. Dtsch Arztebl Int 2022;119:727-34. [PMID: 35972414 DOI: 10.3238/arztebl.m2022.0298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Odio CD, Katzelnick LC. 'Mix and Match' vaccination: Is dengue next? Vaccine 2022;40:6455-62. [PMID: 36195473 DOI: 10.1016/j.vaccine.2022.09.007] [Reference Citation Analysis]
20 Venuto R, Giunta I, Vaccaro M, La Fauci V, Ceccio C, Fedele F, Privitera A, Denaro F, Pantò G, Cortese R, Visalli G, D’amato S, Squeri A, Squeri R, Genovese C. Reactogenicity and Humoral Immune Response after Heterologous Vaxzevria/Comirnaty Vaccination in a Group of Individuals Vaccinated in the AOU Policlinic “G. Martino” (Messina, Italy): A Retrospective Cohort Study. Vaccines 2022;10:1803. [DOI: 10.3390/vaccines10111803] [Reference Citation Analysis]
21 Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, Ferrall L, Hung CF, Wu TC. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 2022;29:82. [PMID: 36243868 DOI: 10.1186/s12929-022-00853-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Capone S, Fusco FM, Milleri S, Borrè S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannacone C, Carsetti R, Folgori A, Camerini R, COVITAR study group. GRAd-COV2 vaccine provides potent and durable immunity in randomised placebo-controlled phase 2 trial (COVITAR).. [DOI: 10.1101/2022.10.08.22280836] [Reference Citation Analysis]
23 Hassert M, Harty JT. Tissue resident memory T cells- A new benchmark for the induction of vaccine-induced mucosal immunity. Front Immunol 2022;13:1039194. [DOI: 10.3389/fimmu.2022.1039194] [Reference Citation Analysis]
24 Helmy SA, El-Morsi RM, Helmy SAM, El-Masry SM. Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. J Drug Deliv Sci Technol 2022;76:103762. [PMID: 36097606 DOI: 10.1016/j.jddst.2022.103762] [Reference Citation Analysis]
25 He M, Huang Y, Wang Y, Liu J, Han M, Xiao Y, Zhang N, Gui H, Qiu H, Cao L, Jia W, Huang S. Metabolomics-based investigation of SARS-CoV-2 vaccination (Sinovac) reveals an immune-dependent metabolite biomarker. Front Immunol 2022;13:954801. [DOI: 10.3389/fimmu.2022.954801] [Reference Citation Analysis]
26 Agrati C, Castilletti C, Battella S, Cimini E, Matusali G, Sommella A, Sacchi A, Colavita F, Contino AM, Bordoni V, Meschi S, Gramigna G, Barra F, Grassi G, Bordi L, Lapa D, Notari S, Casetti R, Bettini A, Francalancia M, Ciufoli F, Vergori A, Vita S, Gentile M, Raggioli A, Plazzi MM, Bacchieri A, Nicastri E, Antinori A, Milleri S, Lanini S, Colloca S, Girardi E, Camerini R, Ippolito G, Vaia F, Folgori A, Capone S. Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. npj Vaccines 2022;7. [DOI: 10.1038/s41541-022-00531-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Scurr MJ, Lippiatt G, Capitani L, Bentley K, Lauder SN, Smart K, Somerville MS, Rees T, Stanton RJ, Gallimore A, Hindley JP, Godkin A. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nat Commun 2022;13:5422. [PMID: 36130936 DOI: 10.1038/s41467-022-32985-8] [Reference Citation Analysis]
28 Chen C, Yang L, Chang W, Huang Y, Chiu C, Shih S, Huang C, Huang KA. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-33146-7] [Reference Citation Analysis]
29 Damerau L, Mühlenbruch G, Evenschor-Ascheid A, Fussen C, Nienhaus A, Terschüren C, Herold R, Harth V. Coronavirus Vaccination: Spike Antibody Levels in Health Workers after Six Months-A Cross-Sectional Study. Int J Environ Res Public Health 2022;19. [PMID: 36141696 DOI: 10.3390/ijerph191811422] [Reference Citation Analysis]
30 Niyomnaitham S, Chatsiricharoenkul S, Toh ZQ, Senawong S, Pheerapanyawaranun C, Phumiamorn S, Licciardi PV, Chokephaibulkit K. Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study. Vaccines 2022;10:1497. [DOI: 10.3390/vaccines10091497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Núñez NG, Schmid J, Power L, Alberti C, Krishnarajah S, Kreutmair S, Unger S, Blanco S, Konigheim B, Marín C, Onofrio L, Kienzler JC, Costa Pereira SD, Ingelfinger F, Pasinovich ME, Castelli JM, Vizzotti C, Schaefer M, Villar-vesga J, Merten CH, Sethi A, Wertheimer T, Lutz M, Vanoaica D, Sotomayor C, Gruppi A, Münz C, Cardozo D, Barbás G, Lopez L, Carreño P, Castro G, Raboy E, Gallego S, Morón G, Cervi L, Acosta Rodriguez EV, Maletto BA, Maccioni M, Becher B, InmunoCovidCba, InViV working group. Distinct immune signatures discriminate SARS-CoV-2 vaccine combinations.. [DOI: 10.1101/2022.09.05.22279572] [Reference Citation Analysis]
32 Takano T, Sato T, Kotaki R, Moriyama S, Shinoda M, Kabasawa K, Shimada N, Kousaka M, Adachi Y, Onodera T, Terahara K, Isogawa M, Matsumura T, Shinkai M, Takahashi Y. Heterologous booster immunization with SARS-CoV-2 spike protein after mRNA vaccine elicits durable and broad antibody responses.. [DOI: 10.21203/rs.3.rs-2014078/v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Leung NHL, Cheng SMS, Cohen CA, Martín-sánchez M, Au NYM, Luk LLH, Tsang LCH, Kwan KKH, Chaothai S, Fung LWC, Cheung AWL, Chan KCK, Li JKC, Ng YY, Kaewpreedee P, Jia JZ, Ip DKM, Poon LLM, Leung GM, Peiris JSM, Valkenburg SA, Cowling BJ. Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study).. [DOI: 10.1101/2022.08.25.22279158] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines Reply to 'cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: A real-life multicentre experience'. J Eur Acad Dermatol Venereol 2022. [PMID: 35972802 DOI: 10.1111/jdv.18531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Rueda-Fernández M, Melguizo-Rodríguez L, Costela-Ruiz VJ, González-Acedo A, Ramos-Torrecillas J, Illescas-Montes R. The current status of COVID-19 vaccines. A scoping review. Drug Discov Today 2022:S1359-6446(22)00306-3. [PMID: 35995361 DOI: 10.1016/j.drudis.2022.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Pascuale CA, Varese A, Ojeda DS, Pasinovich ME, Lopez L, Rossi AH, Rodriguez PE, Miglietta EA, Mazzitelli I, Di Diego Garcia F, Sanchez L, Rouco SO, Gonzalez Lopez Ledesma MM, Zurano JP, Mazzitelli B, Scruzzi G, Barbero P, Cardozo D, Gallego S, Borda M, Diaz M, Ridao F, Rosales AB, Bhon J, Talia JM, Diangelo ME, Lacaze MA, Aime B, Gutierrez SI, Ercole R, Toro R, Tau L, Delaplace L, Compagnucci MF, Sartori C, Desimone I, Echegoyen C, Velazquez P, Testa C, Hozbor D, Docena G, Laino CH, Kreplak N, Pifano M, Barbas G, Rearte A, Vizzotti C, Castelli JM, Geffner J, Gamarnik AV; Laboratorio SeVa Group., Ministerio de Salud de la Provincia de Córdoba Group., UNC-Fac. Cs. Médicas-InViV Group., Ministerio de Salud de la Provincia de La Rioja Group., Ministerio de Salud de la Provincia de San Luis Group., Universidad Nacional de La Plata Group., Ministerio de Salud de la Provincia de Buenos Aires Group. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. Cell Rep Med 2022;3:100706. [PMID: 35926505 DOI: 10.1016/j.xcrm.2022.100706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
37 Klemis V, Schmidt T, Schub D, Mihm J, Marx S, Abu-Omar A, Ziegler L, Hielscher F, Guckelmus C, Urschel R, Wagenpfeil S, Schneitler S, Becker SL, Gärtner BC, Sester U, Sester M. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nat Commun 2022;13:4710. [PMID: 35953492 DOI: 10.1038/s41467-022-32321-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Keddy KH. Vaccine pragmatism in the 21st century. The Lancet Infectious Diseases 2022;22:1097-1098. [DOI: 10.1016/s1473-3099(22)00181-5] [Reference Citation Analysis]
39 Mccann N, O’connor D, Lambe T, Pollard AJ. Viral vector vaccines. Current Opinion in Immunology 2022;77:102210. [DOI: 10.1016/j.coi.2022.102210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Shang L, Cao B. Protein-based vaccine as the booster dose for adults: evidence and beyond. The Lancet Infectious Diseases 2022. [DOI: 10.1016/s1473-3099(22)00447-9] [Reference Citation Analysis]
41 Korodi M, Horváth I, Rákosi K, Jenei Z, Hudák G, Kákes M, Dallos-fejér K, Simai E, Páll O, Staver N, Briciu V, Lupșe M, Flonta M, Almaș A, Birlutiu V, Daniela Lupu C, Magdalena Ghibu A, Pianoschi D, Terza L, Fejer SN. Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.07.040] [Reference Citation Analysis]
42 Li J, Wu S, Guo X, Tang R, Huang B, Chen X, Chen Y, Hou L, Liu J, Zhong J, Pan H, Shi F, Xu X, Li Z, Zhang X, Cui L, Tan W, Chen W, Zhu F, Li J, Wu S, Guo X, Tang R, Huang B, Chen X, Chen Y, Hou L, Liu J, Zhong J, Pan H, Shi F, Xu X, Li Z, Zhang X, Cui L, Tan W, Chen W, Zhu F, Huang H, Gou J, Si W, Wang X, Zhao X, Zhu T. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. The Lancet Respiratory Medicine 2022;10:739-48. [DOI: 10.1016/s2213-2600(22)00087-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
43 Rammauro F, Carrión F, Olivero-Deibe N, Fló M, Ferreira A, Pritsch O, Bianchi S. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. Vaccine 2022:S0264-410X(22)00911-2. [PMID: 35907676 DOI: 10.1016/j.vaccine.2022.07.023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Chen Z, Zhang Y, Wang M, Islam MS, Liao P, Hu Y, Chen X. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. Int J Biol Sci 2022;18:4629-41. [PMID: 35874952 DOI: 10.7150/ijbs.73583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
45 Liu M, Li Y. Advances in COVID-19 Vaccines and New Coronavirus Variants. Front Med (Lausanne) 2022;9:888631. [PMID: 35872788 DOI: 10.3389/fmed.2022.888631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Klastrup V, Stærke NB, Søgaard OS. Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization. Clin Microbiol Infect 2022:S1198-743X(22)00347-0. [PMID: 35843563 DOI: 10.1016/j.cmi.2022.06.032] [Reference Citation Analysis]
47 Andersson NW, Thiesson EM, Laursen MV, Mogensen SH, Kjær J, Hviid A. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study. BMJ 2022;378:e070483. [PMID: 35831006 DOI: 10.1136/bmj-2022-070483] [Reference Citation Analysis]
48 Halilova JG, Fynes-Clinton S, Green L, Myerson J, Wu J, Ruggeri K, Addis DR, Rosenbaum RS. Short-sighted decision-making by those not vaccinated against COVID-19. Sci Rep 2022;12:11906. [PMID: 35831340 DOI: 10.1038/s41598-022-15276-6] [Reference Citation Analysis]
49 Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González-gonzález L, Madrenas L, Güell I, Clotet B, Izquierdo-useros N, Raïch-regué D, Gallemí M, Blanco J, Pradenas E, Trinité B, Prado JG, Blanch-lombarte O, Pérez-caballero R, Plana M, Esteban I, Pastor-quiñones C, Núñez-costa X, Taleb RA, Mcskimming P, Soriano A, Planol J, Anagua JO, Ramos R, Lluch RM, Comes AC, Romero SO, Gomez XM, Sans-pola C, Moltó J, Benet S, Bailón L, Arribas JR, Borobia AM, Parada JQ, Navarro-pérez J, José Forner Giner M, Ortí Lucas R, Vázquez Jiménez MDM, Compán SO, Alvarez-mon M, Troncoso D, Arana-arri E, Meijide S, Imaz-ayo N, García PM, de la Villa Martínez S, Fernández SR, Prat T, Torroella È, Ferrer L. Safety and immunogenicity of the protein-based PHH-IV compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.. [DOI: 10.1101/2022.07.05.22277210] [Reference Citation Analysis]
50 Perkhofer L, Nägele J, Kroschel J, Mayer B, Müller M, Seufferlein T. Acute Reactions After Vaccination Against COVID-19 and Long-Term Antibody Levels. Dtsch Arztebl Int 2022;119:484-5. [PMID: 36342091 DOI: 10.3238/arztebl.m2022.0195] [Reference Citation Analysis]
51 Boongird S, Setthaudom C, Kitpermkiat R, Prasongtanakij S, Srisala S, Chuengsaman P, Nongnuch A, Assanatham M, Kiertiburanakul S, Malathum K, Phuphuakrat A, Bruminhent J. Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3). Vaccines 2022;10:1064. [DOI: 10.3390/vaccines10071064] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Jeong S, Lee N, Lee SK, Cho EJ, Hyun J, Park MJ, Song W, Kim HS. Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers. Front Immunol 2022;13:859019. [PMID: 35720318 DOI: 10.3389/fimmu.2022.859019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Mullender C, da Costa KAS, Alrubayyi A, Pett SL, Peppa D. SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxford Open Immunology 2022;3. [DOI: 10.1093/oxfimm/iqac005] [Reference Citation Analysis]
54 Goldman JD, Gonzalez MA, Rüthrich MM, Sharon E, von Lilienfeld-Toal M. COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. Am Soc Clin Oncol Educ Book 2022;42:1-13. [PMID: 35658503 DOI: 10.1200/EDBK_359656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Jo E. Adverse Reactions of COVID-19 Vaccines. J Clin Otolaryngol Head Neck Surg 2022;33:92-104. [DOI: 10.35420/jcohns.2022.33.2.92] [Reference Citation Analysis]
56 Shaw RH, Liu X, Stuart ASV, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Dejnirattisai W, Dinesh T, Faust SN, Ferreira DM, Finn A, Green CA, Hallis B, Heath PT, Hill H, Lambe T, Lazarus R, Libri V, Long F, Mujadidi YF, Plested EL, Morey ER, Provstgaard-morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screaton GR, Singh N, Turner DPJ, Turner PJ, Vichos I, Walker LL, White R, Nguyen-van-tam JS, Snape MD, Munro AP, Bartholomew J, Presland L, Horswill S, Warren S, Varkonyi-clifford S, Saich S, Adams K, Ricamara M, Turner N, Yee Ting NY, Whittley S, Rampling T, Desai A, Brown CH, Qureshi E, Gokani K, Naker K, Kellett Wright JK, Williams RL, Riaz T, Penciu FD, Carson A, Di Maso C, Mead G, Howe EG, Vichos I, Ghulam Farooq M, Noristani R, Yao XL, Oldfield NJ, Hammersley D, Belton S, Royal S, San Francisco Ramos A, Hultin C, Galiza EP, Crook R, Bula M, Fyles F, Burhan H, Maelin F, Hughes E, Okenyi E. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. The Lancet Respiratory Medicine 2022. [DOI: 10.1016/s2213-2600(22)00163-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
57 Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ 2022;377:e069989. [PMID: 35640925 DOI: 10.1136/bmj-2022-069989] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
58 Hung S, Preclaro IAC, Chung W, Wang C. Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies. Biomedicines 2022;10:1260. [DOI: 10.3390/biomedicines10061260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Reiter R, Von Blanckenburg P, Mutters R, Thiemer J, Geßner R, Seifart U. Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2. Vaccines 2022;10:788. [DOI: 10.3390/vaccines10050788] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, Wan H, Schubert M, Cassaniti I, Wang Y, Sammartino JC, Sun R, Vlachiotis S, Bergami F, Kumagai-Braesch M, Andréll J, Zhang Z, Xue Y, Wenzel EV, Calzolai L, Varani L, Rezaei N, Chavoshzadeh Z, Baldanti F, Hust M, Hammarström L, Marcotte H, Pan-Hammarström Q. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun 2022;13:2670. [PMID: 35562366 DOI: 10.1038/s41467-022-30340-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 26.0] [Reference Citation Analysis]
61 Pilipenko I, Korovkina O, Gubina N, Ekimova V, Ishutinova A, Korzhikova-Vlakh E, Tennikova T, Korzhikov-Vlakh V. Random Copolymers of Lysine and Isoleucine for Efficient mRNA Delivery. Int J Mol Sci 2022;23:5363. [PMID: 35628177 DOI: 10.3390/ijms23105363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Rzymski P, Sikora D, Zeyland J, Poniedziałek B, Kiedik D, Falfushynska H, Fal A. Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. Vaccines 2022;10:754. [DOI: 10.3390/vaccines10050754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
63 Jin P, Guo X, Chen W, Ma S, Pan H, Dai L, Du P, Wang L, Jin L, Chen Y, Shi F, Liu J, Xu X, Zhang Y, Gao GF, Chen C, Feng J, Li J, Zhu F. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS Med 2022;19:e1003953. [PMID: 35617368 DOI: 10.1371/journal.pmed.1003953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
64 Moss P, Berenbaum F, Curigliano G, Grupper A, Berg T, Pather S. Benefit–Risk Evaluation of COVID-19 Vaccination in Special Population Groups of Interest. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.05.067] [Reference Citation Analysis]
65 Abeywickrema M, Goodman AL. COVID-19 vaccine results might inform malaria vaccine strategies. The Lancet Infectious Diseases 2022;22:440-441. [DOI: 10.1016/s1473-3099(22)00139-6] [Reference Citation Analysis]
66 Skorupa M, Szczepanek J, Goroncy A, Jarkiewicz-tretyn J, Ptaszyńska B, Rajewski P, Koper W, Pałgan K, Tretyn A. The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines. Vaccines 2022;10:506. [DOI: 10.3390/vaccines10040506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Barocci S, Orlandi C, Diotallevi A, Buffi G, Ceccarelli M, Vandini D, Carlotti E, Galluzzi L, Rocchi MBL, Magnani M, Casabianca A. Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination. Vaccines (Basel) 2022;10:491. [PMID: 35455240 DOI: 10.3390/vaccines10040491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Iacopetta D, Ceramella J, Catalano A, Saturnino C, Pellegrino M, Mariconda A, Longo P, Sinicropi MS, Aquaro S. COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies. Viruses 2022;14:573. [DOI: 10.3390/v14030573] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
69 Chiuppesi F, Zaia JA, Frankel PH, Stan R, Drake J, Williams B, Acosta AM, Francis K, Taplitz RA, Dickter JK, Dadwal S, Puing AG, Nanayakkara DD, Ash P, Cui Y, Contreras H, La Rosa C, Tiemann K, Park Y, Medina J, Iniguez A, Zhou Q, Karpinski V, Johnson D, Faircloth K, Kaltcheva T, Nguyen J, Kha M, Nguyen VH, Francisco SO, Grifoni A, Wong A, Sette A, Wussow F, Diamond DJ. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. The Lancet Microbe 2022. [DOI: 10.1016/s2666-5247(22)00027-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
70 Marking U, Havervall S, Greilert-norin N, Ng H, Blom K, Nilsson P, Phillipson M, Hober S, Nilsson C, Mangsbo S, Christ W, Klingström J, Gordon M, Åberg M, Thålin C. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Vaccines 2022;10:359. [DOI: 10.3390/vaccines10030359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
71 Willyard C. What the Omicron wave is revealing about human immunity. Nature 2022;602:22-5. [PMID: 35110764 DOI: 10.1038/d41586-022-00214-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
72 Karakaş N, Üçüncüoğlu S, Uludağ D, Karaoğlan BS, Shah K, Öztürk G. Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells 2022;11:465. [DOI: 10.3390/cells11030465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Radhwi OO, Jan H, Waheeb A, Alamri SS, Alahwal HM, Denetiu I, Almanzlawey A, Al-marzouki AF, Almohammadi AT, Bahashwan SM, Barefah AS, Qari MH, Abuzenadah AM, Hashem AM. Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies. Vaccines 2022;10:151. [DOI: 10.3390/vaccines10020151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-mata L, Wan H, Schubert M, Wang Y, Sun R, Cassaniti I, Vlachiotis S, Kumagai-braesch M, Andréll J, Zhang Z, Xue Y, Wenzel EV, Calzolai L, Varani L, Rezaei N, Chavoshzadeh Z, Baldanti F, Hust M, Hammarström L, Marcotte H, Pan-hammarström Q. Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant.. [DOI: 10.1101/2022.01.04.22268755] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
75 Park J, Minn D, Hong S, Jeong S, Kim S, Lee CH, Kim B. Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy. J Korean Med Sci 2022;37:e180. [DOI: 10.3346/jkms.2022.37.e180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, Akbari A, Azcoaga-Lorenzo A, Bradley DT, Fagbamigbe AF, Grange Z, Hall ECR, Joy M, Katikireddi SV, Kerr S, Ritchie L, Murphy S, Owen RK, Rudan I, Shah SA, Simpson CR, Torabi F, Tsang RSM, de Lusignan S, Lyons RA, O'Reilly D, Sheikh A. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet 2022;400:1305-20. [PMID: 36244382 DOI: 10.1016/S0140-6736(22)01656-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR; Com-COV2 study group. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet 2021:S0140-6736(21)02844-0. [PMID: 34942101 DOI: 10.1016/S0140-6736(21)02844-0] [Cited by in Crossref: 192] [Cited by in F6Publishing: 221] [Article Influence: 96.0] [Reference Citation Analysis]
78 Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021;398:2258-76. [PMID: 34863358 DOI: 10.1016/S0140-6736(21)02717-3] [Cited by in Crossref: 308] [Cited by in F6Publishing: 296] [Article Influence: 154.0] [Reference Citation Analysis]
79 Mahase E. Covid-19: "Mix and match" primary vaccines are safe and effective, study finds. BMJ 2021;375:n3030. [PMID: 34876460 DOI: 10.1136/bmj.n3030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Eugenia Toledo-romaní M, García-carmenate M, Valenzuela-silva C, Baldoquín-rodríguez W, Martínez-pérez M, Rodríguez-gonzález M, Paredes-moreno B, Mendoza-hernández I, González-mujica R, Samón-tabio O, Velazco-villares P, Bacallao-castillo JP, Licea-martín E, Rodríguez-ortega M, Herrera-marrero N, Caballero-gonzález E, Egües-torres L, Duartes-gonzález R, García-blanco S, Pérez-cabrera S, Huete-ferreira S, Idalmis-cisnero K, Fonte-galindo O, Meliá-pérez D, Rojas-remedios I, Doroud D, Gouya MM, Biglari A, Van der Stuyft P, Fernández-castillo S, Climent-ruiz Y, Valdes-balbín Y, García-rivera D, Verez-bencomo V, the SOBERANA Phase 3 team. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial.. [DOI: 10.1101/2021.10.31.21265703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
81 Korodi M, Horváth I, Rákosi K, Jenei Z, Hudák G, Kákes M, Dallos-fejér K, Simai E, Páll O, Staver N, Briciu V, Lupşe M, Flonta M, Almaş A, Birlutiu V, Lupu CD, Ghibu AM, Pianoschi D, Terza L, Fejer SN. Longitudinal determination of mRNA-vaccination induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.. [DOI: 10.1101/2021.03.17.21253751] [Reference Citation Analysis]